Nucleic acids and corresponding proteins entitled 191P4D12(b) useful in treatment and detection of cancer

• US 7,968,090 B2
• Filed: 06/22/2010
• Issued: 06/28/2011
• Est. Priority Date: 03/14/2001
• Status: Expired due to Fees

• Current Assignee: Agensys, Inc. (Astellas Pharma Incorporated)
• Original Assignee: Agensys, Inc. (Astellas Pharma Incorporated)
• Inventors: Raitano, Arthur B., Faris, Mary, Ge, Wangmao, Challita-Eid, Pia M., Jakobovits, Aya
• Primary Examiner(s): Aeder; Sean E
• Application Number:
  US12/820,279
• Publication Number:
  US 20100297005A1
• Time in Patent Office: 371 Days
• Field of Search: None
• US Class Current: 424/130.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A novel gene 191P4D12(b) and its encoded protein, and variants thereof, are described wherein 191P4D12(b) exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 191P4D12(b) provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 191P4D12(b) gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 191P4D12(b) can be used in active or passive immunization.

Claims

1. A method of inhibiting growth of a tumor cell that expresses a protein comprising the amino acid sequence of SEQ ID NO:

3, comprising;

contacting said tumor cell with an antibody or antigen binding thereof specifically binds to the protein, wherein the antibody or antigen binding is conjugated to a cytotoxic agent, and upon binding to the protein inhibits the growth of the tumor cell, wherein the cell is from a tissue source selected from the group consisting of prostate, bladder, lung, pancreas, and breast cancer.

2. The method of claim 1, wherein the antibody or antigen binding thereof comprises the variable regions of the heavy chains and light chains of an antibody that binds specifically to the amino acid sequence of SEQ ID NO:

3.

3. The method of claim 1, wherein the antibody is a monoclonal antibody.

4. The method of claim 1, wherein the antibody is a polyclonal antibody.

5. The method of claim 1, wherein the antibody is a fully human antibody.

6. The method of claim 1, wherein the antigen binding of the antibody is an Fab, F(ab′

)₂, Fv or Sfv fragment.

7. The method of claim 1, wherein the antibody is a recombinant protein.

8. The method of claim 7, wherein the recombinant protein comprises the antigen binding region of the antibody.

9. The method of claim 1, wherein the antibody comprises an antigen binding site that specifically binds to an epitope within amino acids of SEQ ID NO:

3.

10. The method of claim 1, wherein the cytotoxic agent is a toxin, a therapeutic agent or a radioisotope.

11. The method of claim 10, wherein the radioisotope selected from the group consisting of ²¹²Bi, ¹³¹I, ¹³¹In, ⁹⁰Y, ¹⁸⁶Re, ²¹¹At, ¹²⁵I, ¹⁸⁸Re, ¹⁵³Sm, ²¹³Bi, ³²P, and Lu.

12. The method of claim 10, wherein the cytotoxic agent is selected from the group consisting of auristatins, auromycins, maytansinoids, yttrium, bismuth, ricin, ricin A-chain, combrestatin, duocarmycins, dolostatins, doxorubicin, daunorubicin, taxol, cisplatin, cc1065, ethidium bromide, mitomycin, etoposide, tenopo side, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin, diphtheria toxin, Pseudomonas exotoxin (PE) A, PE40, abrin, abrin A chain, modeccin A chain, alpha-sarcin, gelonin, mitogellin, retstrictocin, phenomycin, enomycin, curicin, crotin, calicheamicin, Sapaonaria officinalis inhibitor, and glucocorticoid.

13. A method of inhibiting growth of a tumor cell that expresses a protein comprising the amino acid sequence of SEQ ID NO:

3, comprising;

contacting said tumor cell with an antibody-agent conjugate, wherein the conjugate comprises an antibody or antigen binding thereof that binds specifically to the protein and a cytotoxic agent conjugated to the antibody or fragment, and upon binding to the protein, the conjugate inhibits growth of the tumor cell, wherein the cell is from a tissue source selected from the group consisting of prostate, bladder, lung, pancreas, and breast cancer.

14. The method of claim 13, wherein the antibody of the antibody-agent conjugate is a monoclonal antibody or a polyclonal antibody.

15. The method of claim 13, wherein the antigen binding of the antibody of the antibody-agent conjugate is an Fab, F(ab′

)₂, Fv, or Sfv fragment.

16. The method of claim 13, wherein the cytotoxic agent is a toxin, a therapeutic agent, or a radioisotope.

17. The method of claim 16, wherein the radioisotope is selected from the group consisting of ²¹²Bi, ¹³¹I, ¹³¹In, ⁹⁰Y, ¹⁸⁶Re, ²¹¹At, ¹²⁵I, ¹⁸⁸Re, ¹⁵³Sm, ²¹³Bi, ³²P, and Lu.

18. The method of claim 16, wherein the cytotoxic agent is selected from the group consisting of auristatins, auromycins, maytansinoids, yttrium, bismuth, ricin, ricin A-chain, combrestatin, duocarmycins, dolostatins, doxorubicin, daunorubicin, taxol, cisplatin, cc1065, ethidium bromide, mitomycin, etoposide, tenopo side, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin, diphtheria toxin, Pseudomonas exotoxin (PE) A, PE40, abrin, abrin A chain, modeccin A chain, alpha-sarcin, gelonin, mitogellin, retstrictocin, phenomycin, enomycin, curicin, crotin, calicheamicin, Sapaonaria officinalis inhibitor, and glucocorticoid.